Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 15-Oct-2012

Today BioGaia has signed an agreement with Ferozsons Laboratories Limited, for the exclusive rights to sell BioGaia’s probiotic drops and tablets in Pakistan. The products will be sold under the BioGaia brand and launch is planned to 2013.

Ferozsons Laboratories Limited is one of Pakistan\'s leading pharmaceutical companies. Several of the company’s brands are market leaders in the fields of gastroenterology, cardiology and oncology. Ferozsons Laboratories Limited is focused on medical marketing and has a large medical field force. The company has been listed on Pakistan’s three Stock Exchanges since 1960.

Both the BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain BioGaia’s patented and well researched probiotic strain Lactobacillus reuteri Protectis. Today the drops are available in 52 countries and the tablets in 46 countries.

“We are pleased with the agreement with Ferozsons Laboratories Limited. As Pakistan has a population of 187 million people the world’s sixth most populous and in addition a large proportion is children, the potential for our probiotic products should be good”, says Peter Rothschild, Chief Executive Officer, BioGaia.

Go to previous page